---
id: nccn-melanoma-2024
title: "NCCN 2024 Clinical Practice Guidelines: Cutaneous Melanoma"
short_title: "NCCN Melanoma 2024"

organization: National Comprehensive Cancer Network
collaborators: null
country: US
url: https://www.nccn.org/guidelines/
doi: null
pmid: null
open_access: false

specialty: oncology
guideline_type: clinical-practice
evidence_system: NCCN
conditions:
  - melanoma
  - cutaneous melanoma
  - metastatic melanoma
tags:
  - immunotherapy
  - BRAF inhibitors
  - sentinel lymph node biopsy
  - adjuvant therapy
  - PD-1 inhibitors

publication_date: 2024-06-01
previous_version_date: 2023-06-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 NCCN clinical practice guideline on the diagnosis, staging, and treatment of cutaneous melanoma.

## Key Recommendations

### Diagnosis
- **Biopsy**: Excisional biopsy with narrow margins is preferred. Shave biopsy acceptable for flat lesions if full depth is obtained.
- **Pathology**: Report Breslow thickness, ulceration, mitotic rate, microsatellites, margins.

### Staging Workup
- **Early Stage (T1-T2)**: No routine imaging for low-risk.
- **Intermediate-High Risk (≥T2b or clinically positive nodes)**: Consider baseline imaging (CT, PET-CT, MRI brain).
- **Sentinel Lymph Node Biopsy (SLNB)**: Discuss/offer for melanoma ≥T1b; recommended for T2+ or ulcerated T1a.

### Wide Local Excision Margins
- In situ: 0.5-1 cm.
- ≤1 mm thickness: 1 cm.
- 1.01-2 mm: 1-2 cm.
- >2 mm: 2 cm.

### Adjuvant Therapy (Resected Stage IIB/C, III)
- **Pembrolizumab or Nivolumab**: Standard of care for resected high-risk melanoma (stage IIB-III). Improves recurrence-free survival.
- **Dabrafenib + Trametinib**: Alternative for BRAF V600-mutant melanoma.

### Unresectable / Metastatic Melanoma

#### First-Line
- **BRAF Wild-Type**: PD-1 inhibitor (nivolumab, pembrolizumab) or combination ipilimumab + nivolumab.
- **BRAF Mutant**: PD-1 inhibitor or ipilimumab + nivolumab (preferred); OR BRAF/MEK inhibitor combination (dabrafenib + trametinib, encorafenib + binimetinib).

#### Subsequent Lines
- Switch class: If progressed on PD-1, consider ipilimumab + nivolumab or BRAF/MEK (if BRAF mutant). TIL therapy (lifileucel) for heavily pretreated patients.

### Molecular Testing
- BRAF mutation testing recommended for stage III/IV.
